➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Boehringer Ingelheim
Colorcon
Medtronic
Dow

Last Updated: September 21, 2021

DrugPatentWatch Database Preview

Claims for Patent: 9,999,618


Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,999,618
Title:Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
Inventor(s): Castelli; Jeff (New Hope, PA), Lockhart; David J. (Del Mar, CA)
Assignee: Amicus Therapeutics, Inc. (Cranbury, NJ)
Application Number:15/213,920
Patent Claims: 1. A method of reducing left ventricular mass index (LVMi) in a patient having Fabry disease, the method comprising administering to the patient a formulation comprising an effective amount of 1-deoxygalactonojirimycin or salt thereof every other day for reducing the patient's LVMi, wherein the effective amount is about 123 mg free base equivalent (FBE).

2. The method of claim 1, wherein the patient has left ventricular hypertrophy (LVH) prior to initiating administration of the 1-deoxygalactonojirimycin or salt thereof.

3. The method of claim 1, wherein the 1-deoxygalactonojirimycin or salt thereof enhances a-galactosidase A activity.

4. The method of claim 1, wherein the patient is administered about 123 mg of 1-deoxygalactonojirimycin every other day.

5. The method of claim 1, wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

6. The method of claim 1, wherein the formulation comprises an oral dosage form.

7. The method of claim 6, wherein the oral dosage form comprises a tablet, a capsule or a solution.

8. A method of reducing podocyte globotriaosylceramide (GL-3) in a patient having Fabry disease, the method comprising administering to the patient a formulation comprising an effective amount of 1-deoxygalactonojirimycin or salt thereof every other day for reducing the patient's podocyte GL-3, wherein the effective amount is about 123 mg free base equivalent (FBE).

9. The method of claim 8, wherein the 1-deoxygalactonojirimycin or salt thereof enhances a-galactosidase A activity.

10. The method of claim 8, wherein the patient is administered about 123 mg of 1-deoxygalactonojirimycin every other day.

11. The method of claim 8, wherein the patient is administered about 150 mg of migalastat hydrochloride every other day.

12. The method of claim 8, wherein the formulation comprises an oral dosage form.

13. The method of claim 12, wherein the oral dosage form comprises a tablet, a capsule or a solution.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.